Specific immune response and pathological findings in BALB/c mice inoculated with recombinat BCG expressing HIV-1 antigen

• Main Authors: Witthawat Wiriyarat, Sanya Sukpanichnant, Nopporn Sittisombut, Kruavon Balanchandra, Duanthanorm Promkhatkaew, Raywadee Butraporn, Ruengpung Sutthent, Jotika Boonlong, Kazuhiro Matsuo, Mitsuo Honda, Paijit Warachit, Pilaipan Puthavathana
• Format: Journal
• Published: 2018
• Subjects: Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=20344390518&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/62416
• Institution: Chiang Mai University

Recombinant BCGs (rBCGs) containing extrachromosomal plasmids with different HIV-1 insert sequences: nef, env (V3J1 and E9Q), gag p17 or whole gag p55 were evaluated for their immunogenicity, safety and persistent infection in BALB/c mice. Animal injected with, rBCG-pIJKV3J1, rBCG-pSO gag p17 or rBCG-pSO gag p55 could elicit lymphocyte proliferation as tested by specific HIV-1 peptides or protein antigen. Inoculation with various concentration of rBCG-pSO gag p55 generated satisfactory specific lymphocyte proliferation in dose escalation trials. The rBCG-pSO gag p55 recovered from spleen tissues at different time interval post-inoculation could express the HIV protein as determined by ELISA p24 antigen detection kit. This result indicated that the extrachromosomal plasmid was stable and capable to express Gag protein. It was also demonstrated that rBCGs did not cause serious pathological change in the inoculated animals. The present study suggested the role of BCG as a potential vehicle for using in HIV vaccine development.